drugset / Trial / NCT06470841
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Timeline
- Start
- 2024-09-20
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Subject | G | Unknown | 250 ug/m2 | Subcutaneous |
| Subject | Homoharringtonine | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |